CeraPedics (Lakewood, CO) developing products for the orthopedic bone substitute market announced the close of a $12.25M private equity financing from OrbiMed Advisors. The Company’s products utilize a proprietary small peptide called P-15™. This peptide has been identified to play a role in initiating the formation of bone. CeraPedics’ products may provide a safe, efficacious, [...]

• 159http://clsdf.com/2007/02/cerapedics-closes-12-25m-pe-financing/CeraPedics+Closes+%2412.25M+PE+Financing2007-03-01+05%3A14%3A00admin

Dave Cohen, a Boulder-based serial entrepreneur, active angel investor, co-founder and Executive Director of TechStars, technologist, author of Colorado Startups, and friend, invited me to guest post on his blog. What an honor and privilege to cover in a bit more detail for Dave’s readership the bio side of the Venture Capital in the Rockies [...]

• 158http://clsdf.com/2007/02/me%e2%80%a6a-guest-blogger/Me%E2%80%A6A+Guest+Blogger%3F2007-02-26+16%3A32%3A00admin

Don’t miss out on the opportunity to listen to Michael Bristow, M.D., Ph.D., on 8 March 8:00 – 9:00am, speak about the history of Myogen. The Myogen tale is a fascinating story and an incredible regional (and national) success. Where: Holland & Hart 555 17th St. Suite 3200 Denver

• 157http://clsdf.com/2007/02/hh-bioentrepreneurs-club/H%26amp%3BH+Bioentrepreneurs+Club2007-02-26+15%3A50%3A00admin

Sometimes I simply forget how beautiful Colorado is. It is especially easy to do when Boulder’s Flatirons frame the daily experience. Getting up to the high country for the VC in the Rockies meeting did enable some moments of pause to recalibrate…stop, look and listen. It was easy to do at the Ritz Carlton – [...]

• 156http://clsdf.com/2007/02/marshmallow-pit-oh-my/Marshmallow+Pit%3F+Oh+My%212007-02-22+17%3A26%3A00admin

Colorado State University announced MicroRx, an entity designed to ally academia and commercial enterprise to ultimately accelerate the bench-to-bedside process. Infectious Disease is the focus of this first CSU Supercluster which was borne out of CSU Ventures, lead by Mark Wdowik. CSU is an international center of excellence for the study of infectious disease. The [...]

• 155http://clsdf.com/2007/02/microrx-infectious-disease-supercluster/MicroRx%3A+Infectious+Disease+Supercluster2007-02-20+18%3A07%3A00admin

Happily tracking the progress of Gilead Sciences, Inc. (NASDAQ: GILD) Ambrisentan asset; for the treatment of pulmonary arterial hypertension. Gilead’s recent announcement that the FDA has accepted for filing and granted a priority review for the NDA is exciting news for the Colorado bio-scape. This approval may result in an accelerated review with an expectation [...]

• 154http://clsdf.com/2007/02/ambrisentan-moving-closer-to-approval/Ambrisentan+Moving+Closer+to+Approval2007-02-17+03%3A54%3A00admin

Glucon (Boulder) developer of a blood glucose measurement system raised an undisclosed amount of Series D funding. The deal was led by the 3i Group and was joined by Sequel Venture Partners, Quest Capital Partnership, Hunt Ventures and previous investors Aurum Ventures, Giza Venture Capital, MKI, Infinity Venture Capital Fund and Ascend Technology Ventures.

• 153http://clsdf.com/2007/02/glucon-inc-series-d-undisclosed/Glucon%2C+Inc.%3A+Series+D+Undisclosed2007-02-05+15%3A25%3A00admin

iBalance Medical (Boulder) is developing an improved method for completing an orthopedic surgical procedure called high tibial osteotomy. The company provides the surgical tools and implant for this knee malalignment corrective surgery. Back in October of 2005 I wrote about the $8.24M first tranche (here). The company has recently announced a second $5.26M tranche (also [...]

• 152http://clsdf.com/2007/02/ibalance-rounds-out-13-5m-series-a/iBalance+Rounds+Out+%2413.5M+Series+A2007-02-01+19%3A48%3A00admin

Lot’s of action transpiring at Allos Therapeutics (NASDAQ: ALTH) since Paul Berns has taken over the reigns. We should expect a $50.5M financing to close tomorrow courtesy of Merrill, where 9M shares of common are being floated at $6 less underwriting fees and expenses, much of which to be gobbled up by Baker Brothers Life [...]

• 151http://clsdf.com/2007/02/action-at-allos/Action+At+Allos2007-02-01+19%3A40%3A00admin